Morpholine → N-(5-chloro-2-fluorophenyl)-4-(1-hydroxy-2-morpholinoethyl)-N-isobutylbenzenesulfonamide

HRID 1487066Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1487066
[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([F:25])=[C:6]([N:8]([CH2:21][CH:22]([CH3:24])[CH3:23])[S:9]([C:12]2[CH:17]=[CH:16][C:15]([CH:18]3[CH2:20][O:19]3)=[CH:14][CH:13]=2)(=[O:11])=[O:10])[CH:7]=1.[NH:26]1[CH2:31][CH2:30][O:29][CH2:28][CH2:27]1>C(O)C>[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([F:25])=[C:6]([N:8]([CH2:21][CH:22]([CH3:24])[CH3:23])[S:9]([C:12]2[CH:17]=[CH:16][C:15]([CH:18]([OH:19])[CH2:20][N:26]3[CH2:31][CH2:30][O:29][CH2:28][CH2:27]3)=[CH:14][CH:13]=2)(=[O:10])=[O:11])[CH:7]=1

Komponenten

4

Reaktionsbedingungen

Temperatur
50 °C

Versuchsvorschrift

To a stirred solution of N-(5-chloro-2-fluorophenyl)-N-isobutyl-4-(oxiran-2-yl)benzenesulfonamide (200 mg, 0.521 mmol) in ethanol (2 mL) at 25° C. was added morpholine (0.045 ml, 0.521 mmol) and the reaction mixture stirred at 50° C. for 24 hours. The mixture was then purified by mass directed autoprep (ammonium carbonate modifier). The appropriate fractions were combined and evaporated in vacuo to give the required product, 51.4 mg. LCMS [LCMS2] Rt 1.25 min, m/z (ES+) 471 (M+H).

Aufarbeitung

  1. customThe mixture was then purified by mass
  2. customevaporated in vacuo

Quellen und Nachweise

ORD-Eintrag
ord-e504f2459d394d45b64471836712f15a
Quelldatensatz
uspto-grants-2016_08
Patentnummer
US09428452B2

Notizen zur Reaktion

Wird geladen…